Sanofi (NASDAQ:SNY - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 5,290,000 shares, an increase of 25.7% from the December 31st total of 4,210,000 shares. Based on an average daily trading volume, of 2,420,000 shares, the days-to-cover ratio is currently 2.2 days. Approximately 0.2% of the shares of the company are short sold.
Several equities research analysts have commented on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research note on Thursday. Finally, StockNews.com lowered shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $60.00.
Read Our Latest Report on Sanofi
A number of institutional investors have recently added to or reduced their stakes in SNY. Hara Capital LLC raised its stake in shares of Sanofi by 16.2% during the fourth quarter. Hara Capital LLC now owns 4,888 shares of the company's stock worth $236,000 after acquiring an additional 680 shares in the last quarter. Cardinal Capital Management grew its holdings in shares of Sanofi by 1.9% during the 4th quarter. Cardinal Capital Management now owns 68,805 shares of the company's stock valued at $3,318,000 after purchasing an additional 1,282 shares during the last quarter. Kestra Investment Management LLC purchased a new position in Sanofi in the 4th quarter worth $84,000. Sierra Ocean LLC bought a new stake in Sanofi in the fourth quarter worth $44,000. Finally, Keystone Financial Services boosted its position in Sanofi by 2.0% during the fourth quarter. Keystone Financial Services now owns 13,883 shares of the company's stock valued at $670,000 after buying an additional 278 shares during the period. Institutional investors own 14.04% of the company's stock.
NASDAQ SNY traded up $0.19 on Friday, hitting $54.34. The stock had a trading volume of 3,199,286 shares, compared to its average volume of 2,300,899. The firm has a 50-day moving average of $49.24 and a 200-day moving average of $52.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 52-week low of $45.22 and a 52-week high of $58.97. The company has a market capitalization of $137.91 billion, a price-to-earnings ratio of 27.72, a price-to-earnings-growth ratio of 1.21 and a beta of 0.57.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Equities analysts expect that Sanofi will post 3.82 EPS for the current year.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.